Xponance Inc. Sells 4,479 Shares of Bath & Body Works, Inc. (NYSE:BBWI)

Xponance Inc. decreased its holdings in Bath & Body Works, Inc. (NYSE:BBWI) by 13.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,429 shares of the company’s stock after selling 4,479 shares during the quarter. Xponance Inc.’s holdings in Bath & Body Works were worth $1,270,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Shell Asset Management Co. grew its holdings in shares of Bath & Body Works by 180.0% during the 3rd quarter. Shell Asset Management Co. now owns 56,344 shares of the company’s stock worth $1,904,000 after acquiring an additional 36,222 shares during the period. Pearl River Capital LLC raised its holdings in Bath & Body Works by 145.6% in the third quarter. Pearl River Capital LLC now owns 31,364 shares of the company’s stock worth $1,060,000 after purchasing an additional 18,596 shares in the last quarter. Impax Asset Management Group plc lifted its position in Bath & Body Works by 305.6% during the fourth quarter. Impax Asset Management Group plc now owns 356,910 shares of the company’s stock valued at $15,404,000 after buying an additional 268,913 shares during the period. Aigen Investment Management LP bought a new stake in shares of Bath & Body Works during the 3rd quarter valued at $1,697,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Bath & Body Works by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 25,689,543 shares of the company’s stock valued at $868,307,000 after buying an additional 67,920 shares in the last quarter. Institutional investors own 95.14% of the company’s stock.

Bath & Body Works Stock Performance

Shares of NYSE:BBWI opened at $45.60 on Thursday. The firm has a market cap of $10.26 billion, a price-to-earnings ratio of 11.84, a price-to-earnings-growth ratio of 1.43 and a beta of 1.86. The business has a 50-day simple moving average of $46.21 and a two-hundred day simple moving average of $40.40. Bath & Body Works, Inc. has a fifty-two week low of $27.30 and a fifty-two week high of $50.34.

Bath & Body Works (NYSE:BBWI) last announced its quarterly earnings results on Thursday, February 29th. The company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.21. The firm had revenue of $2.91 billion during the quarter, compared to analyst estimates of $2.84 billion. Bath & Body Works had a net margin of 11.82% and a negative return on equity of 37.01%. The business’s revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the business posted $1.86 earnings per share. As a group, research analysts predict that Bath & Body Works, Inc. will post 3.3 earnings per share for the current year.

Bath & Body Works Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 8th. Stockholders of record on Friday, February 23rd were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a $0.80 annualized dividend and a dividend yield of 1.75%. Bath & Body Works’s payout ratio is 20.78%.

Wall Street Analyst Weigh In

BBWI has been the subject of several research reports. TD Cowen increased their price target on shares of Bath & Body Works from $35.00 to $55.00 and gave the stock an “outperform” rating in a research note on Friday, March 1st. Barclays lowered shares of Bath & Body Works from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $37.00 to $45.00 in a report on Thursday, January 4th. Telsey Advisory Group reaffirmed an “outperform” rating and set a $53.00 price objective on shares of Bath & Body Works in a research report on Friday, April 5th. BMO Capital Markets boosted their target price on Bath & Body Works from $48.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. Finally, Evercore ISI increased their target price on Bath & Body Works from $30.00 to $45.00 and gave the stock an “in-line” rating in a research note on Friday, March 1st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $46.73.

Insider Transactions at Bath & Body Works

In related news, insider Thomas E. Mazurek sold 4,285 shares of Bath & Body Works stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $48.89, for a total value of $209,493.65. Following the completion of the sale, the insider now owns 45,992 shares of the company’s stock, valued at $2,248,548.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.19% of the company’s stock.

Bath & Body Works Profile

Bath & Body Works, Inc operates a specialty retailer of home fragrance, body care, and soaps and sanitizer products. It sells its products under the Bath & Body Works, White Barn, and other brand names through retail stores and e-commerce sites located in the United States and Canada, as well as through international stores operated by partners under franchise, license, and wholesale arrangements.